HER2-POSITIVE BREAST CARCINOMA
Clinical trials for HER2-POSITIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to stop HER2+ breast cancer relapse
Disease control OngoingThis phase III trial tests whether adding tucatinib to standard T-DM1 therapy works better than T-DM1 alone at preventing breast cancer from coming back. It involves over 1,000 patients with HER2-positive breast cancer who still have cancer cells after initial treatment. The stud…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug DS-8201a shows promise in targeting Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing a drug called DS-8201a in 62 adults with advanced HER2-positive solid tumors that have not responded to standard treatments. The drug works by attaching to the HER2 protein on cancer cells and damaging their DNA, which may kill the cells. Researc…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy shows promise for aggressive breast cancer
Disease control OngoingThis study tests a new combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 46 women with advanced ca…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
PET scans may guide breast cancer treatment before surgery
Diagnosis OngoingThis phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New PET scan could predict which breast cancer patients respond to targeted therapy
Diagnosis OngoingThis phase 2 trial is testing whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to trastuzumab and pertuzumab before surgery. The study involves 18 women with locally advanced HER2-positive breast cancer. The g…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
Can vaccines keep breast cancer away? new study tests two options
Prevention OngoingThis study tests two different vaccines designed to prevent HER-2 positive breast cancer from coming back in people who have already completed initial treatment. About 119 participants who had surgery after chemotherapy will receive one of the two vaccines, followed by booster sh…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Prevention
Last updated Jun 27, 2026 09:10 UTC
-
Blood test could spot hidden cancer cells after breast cancer surgery
Knowledge-focused TerminatedThis study was designed to see if a blood test that looks for tiny pieces of tumor DNA (called ctDNA) could find leftover cancer cells in people with early-stage breast cancer after standard treatment. The goal was to help doctors decide who might need more therapy. However, the …
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC